OrPhi Therapeutics Inc., is researching a therapy that would treat a blood disorder, cerebral amyloid angiopathy or _CAA, which can cause strokes They are also involved in researching a genetic form of the disease GM2 gangliosidoses.
Founded by John W Steele IV IRACDA a postdoctoral fellow at UC San Diego with the idea of commercializing its various researches on Alzheimers disease, proteinopathies, and neurodegeneration.In support of Carlsbad Life Science Incubator.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/orphic-therapeutics” connections=”true” suffix=””]
OrPhis Chaperone based approach acts upstream of the immunotherapies by preventing the formation of toxic A_ oligomers inside neurons without altering normal A_ processing and function.
In Sep 2017, Orphi Therapeutics was awarded $860K SBIR phase 2 grant.
In 2015, Orphi Therapeutics was awarded with two SBIR phase 1 grants, first of $ 225,000 to a study for Alzhiemers Disease and the other worth $ 150,000, for GM2 Gangliosidoses.
Recover your password.
A password will be e-mailed to you.